Trials / Conditions / ALK-Positive Anaplastic Large Cell Lymphoma
ALK-Positive Anaplastic Large Cell Lymphoma
6 registered clinical trials studyying ALK-Positive Anaplastic Large Cell Lymphoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Unknown | Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma NCT05934045 | University Hospital, Toulouse | — |
| Unknown | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL NCT04796857 | Huiqiang Huang | Phase 1 / Phase 2 |
| Unknown | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL NCT04476459 | Huiqiang Huang | Phase 1 / Phase 2 |
| Unknown | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma NCT04058470 | Huiqiang Huang | Phase 1 / Phase 2 |
| Unknown | Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL NCT03707847 | Mingzhi Zhang | Phase 4 |
| Completed | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451 | BeiGene | Phase 2 |